These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 32695874)

  • 1. Alzheimer's disease drug development pipeline: 2020.
    Cummings J; Lee G; Ritter A; Sabbagh M; Zhong K
    Alzheimers Dement (N Y); 2020; 6(1):e12050. PubMed ID: 32695874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease drug development pipeline: 2022.
    Cummings J; Lee G; Nahed P; Kambar MEZN; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2022; 8(1):e12295. PubMed ID: 35516416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease drug development pipeline: 2021.
    Cummings J; Lee G; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2021; 7(1):e12179. PubMed ID: 34095440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease drug development pipeline: 2023.
    Cummings J; Zhou Y; Lee G; Zhong K; Fonseca J; Cheng F
    Alzheimers Dement (N Y); 2023; 9(2):e12385. PubMed ID: 37251912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease drug development pipeline: 2019.
    Cummings J; Lee G; Ritter A; Sabbagh M; Zhong K
    Alzheimers Dement (N Y); 2019; 5():272-293. PubMed ID: 31334330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Cummings J; Zhou Y; Lee G; Zhong K; Fonseca J; Cheng F
    Alzheimers Dement (N Y); 2024; 10(2):e12465. PubMed ID: 38659717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease drug development pipeline: 2018.
    Cummings J; Lee G; Ritter A; Zhong K
    Alzheimers Dement (N Y); 2018; 4():195-214. PubMed ID: 29955663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposed agents in the Alzheimer's disease drug development pipeline.
    Bauzon J; Lee G; Cummings J
    Alzheimers Res Ther; 2020 Aug; 12(1):98. PubMed ID: 32807237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's disease drug development pipeline: 2017.
    Cummings J; Lee G; Mortsdorf T; Ritter A; Zhong K
    Alzheimers Dement (N Y); 2017 Sep; 3(3):367-384. PubMed ID: 29067343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification.
    Cummings JL; Osse AML; Kinney JW
    Drugs; 2023 Oct; 83(15):1387-1408. PubMed ID: 37728864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's drug-development pipeline: 2016.
    Cummings J; Morstorf T; Lee G
    Alzheimers Dement (N Y); 2016 Nov; 2(4):222-232. PubMed ID: 29067309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.
    Khan A; Corbett A; Ballard C
    Expert Rev Neurother; 2017 Jul; 17(7):683-695. PubMed ID: 28490260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Who funds Alzheimer's disease drug development?
    Cummings J; Bauzon J; Lee G
    Alzheimers Dement (N Y); 2021; 7(1):e12185. PubMed ID: 34095442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease drug-development pipeline: few candidates, frequent failures.
    Cummings JL; Morstorf T; Zhong K
    Alzheimers Res Ther; 2014; 6(4):37. PubMed ID: 25024750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates.
    Hroudová J; Fišar Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Aug; 134():111069. PubMed ID: 38917881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Alzheimer's disease drug development landscape.
    van Bokhoven P; de Wilde A; Vermunt L; Leferink PS; Heetveld S; Cummings J; Scheltens P; Vijverberg EGB
    Alzheimers Res Ther; 2021 Nov; 13(1):186. PubMed ID: 34763720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Old Drugs with New Tricks: Paradigm in Drug Development Pipeline for Alzheimer's Disease.
    Dalvi T; Dewangan B; Das R; Rani J; Shinde SD; Vhora N; Jain A; Sahu B
    Cent Nerv Syst Agents Med Chem; 2020; 20(3):157-176. PubMed ID: 33087034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the horizon-the value and promise of the global pipeline of Alzheimer's disease therapeutics.
    Cole MA; Seabrook GR
    Alzheimers Dement (N Y); 2020; 6(1):e12009. PubMed ID: 32405530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer's Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion.
    Esquer A; Blanc F; Collongues N
    Neurol Ther; 2023 Dec; 12(6):1883-1907. PubMed ID: 37812325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.